Trial Profile
Phase I/II Study of Pembrolizumab in Patients With Relapsed or Refractory Extranodal NK/T- Cell Lymphoma (ENKTL), Nasal Type and EBV-associated Diffuse Large B Cell Lymphomas (EBV-DLBCL)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Extranodal NK-T-cell lymphoma
- Focus Adverse reactions
- 05 May 2021 Planned End Date changed from 12 Mar 2023 to 19 Aug 2020.
- 05 May 2021 Planned primary completion date changed from 12 Mar 2022 to 19 Aug 2020.
- 05 May 2021 Status changed from active, no longer recruiting to discontinued due to poor accrual.